Two Sigma Investments, LP Clovis Oncology, Inc. Transaction History

Two Sigma Investments, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $395,929 - $1.86 Million	-628,459 Reduced 89.37%	74,712 $134,000
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $1.01 Million - $2.21 Million	703,171 New	703,171 $1.42 Million
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $45,630 - $80,444	-16,900 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $68,614 - $98,020	16,900 New	16,900 $75,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $3.2 Million - $17.5 Million	-1,065,298 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $3.41 Million - $13.3 Million	867,370 Added 438.23%	1,065,298 $4.19 Million
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $2.24 Million - $4.48 Million	-174,677 Reduced 46.88%	197,928 $2.94 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $6.58 Million - $11.3 Million	372,605 New	372,605 $9.25 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.